Q4 not far away: name of Brazil pharma partner onceANIVSA approval obtained, per Pidduck....targeting Q4 this year for release of more information and the candy....sounds like Mr. Pidduck can see the order potential from that top tier generic pharma customer Brazil by his statement below and what is 'substantial'? Well Pidduck said that they are targeting to be profitable in Q1, 2024 so that would be my definition of substanatial for the time being...enough to make them go EPS positive! Once Oct 1 arrives, it's open season for that news to arrive at any time.
It is anticipated the delivery of additional products could begin in Q1 2024, and substantially increase the current Brazilian revenue. (2)